Helicobacter Pylori Non-Invasive Testing Market

Helicobacter Pylori Non-Invasive Testing Market Outlook (2023 to 2033)

Expanding at a CAGR of 4.8%, the global helicobacter pylori non-invasive testing market is forecasted to increase from a valuation of US$ 500 million in 2023 to US$ 800 million by the end of 2033. Only urea breath tests offer accuracy in determining whether helicobacter pylori infection is active or eradicated.

Helicobacter pylori infection, or H. pylori, is the most prevalent bacterial infection, affecting the digestive tract and inner stomach lining. Helicobacter pylori infection is the most prominent cause of dyspepsia, peptic ulcers, and gastric adenocarcinoma.

Helicobacter pylori can also be found in persons who have no symptoms but are at risk for developing these disorders. Helicobacter pylori non-invasive tests are used to assist identify whether H. pylori is the root of these issues.

Since helicobacter pylori infection is typically asymptomatic, the majority of infected individuals are unaware of their condition. Helicobacter pylori Infections are more likely to occur in children.

Patients who have peptic ulcers caused by helicobacter pylori typically experience symptoms such as nausea, vomiting, loss of appetite, and persistent burping. Peptic ulcers can occasionally cause serious side effects such as blockage in the stomach lining, internal bleeding, or perforation.

The adoption of non-invasive tests for diagnosing helicobacter pylori infection and subsequent treatment is rising among healthcare professionals. The availability of new and advanced non-invasive tests such as real-time PCR and chemiluminescence immunoassay (CLIA) is anticipated to boost market growth.

The accuracy and sensitivity of these approaches have improved as a result of new developments in helicobacter pylori detection techniques during the past few years. The demand for these techniques has expanded as a result of their greater acceptance among healthcare practitioners.

Non-invasive tests are preferred for helicobacter pylori infection testing by both patients and healthcare professionals worldwide due to the rapid turnaround time for test results, improved patient compliance, and less discomfort often associated with invasive procedures. These tests are also highly accurate and specific, which helps in making the right diagnosis of helicobacter pylori infection. In comparison to invasive endoscopic alternatives, non-invasive diagnostics are more affordable.

One of the main causes of the spread of helicobacter pylori infections is overcrowding. Other important causes include poor sanitation, poor diet, bad personal hygiene, and unhygienic conditions. One of the factors driving market expansion is the rise in awareness of this infection among the general public worldwide. Growing public awareness of the diagnosis of helicobacter pylori, and new product introductions are boosting market growth.

Report Attributes	Details
H. Pylori Non-Invasive Testing Market Size (2023)	US$ 500 Million
Projected Market Value (2033)	US$ 800 Million
Global Market Growth Rate (2023 to 2033)	4.8% CAGR
Market Share of Urea Breath Tests	50%
Key Companies Profiled	Meridian Bioscience Inc.; Agilent Technologies; Sekisui Diagnostics; Roche Holding AG; Bio-Rad Laboratories; Alpha Laboratories; Thermo Fisher Scientific; EKF Diagnostics; Quidel; Cardinal Health; Danaher; Coris BioConcept

Why is Helicobacter Pylori Non-Invasive Testing Gaining High Prominence Worldwide?

“Growing Prevalence of Gastric and Duodenal Illnesses”

Rising prevalence of gastric and duodenal illnesses is driving the demand for helicobacter pylori non-invasive testing. Gastric cancer and peptic ulcer disease are both deeply influenced by helicobacter pylori infection, which is generally asymptomatic.

Non-invasive testing systems are typically used as the first line of treatment for helicobacter pylori infections. The market is growing due to the popularity of the urea breath test (UBT) and stool antigen research (STR), both of which are used to identify diseases.

Another important factor influencing the market is the requirement for effective anti-microbial treatment. There is a need for more research to truly understand the effectiveness of non-invasive diagnostic tests because each test has a different range of sensitivity and specificity. The market is growing as a result of advancements in laboratory serological assay.

As the risk of helicobacter pylori infection rises with age, the prevalence of gastric disease is noticeably higher in the elderly population. Age-related stomach lining loss makes it easier for bacteria to pass across the barrier, which helps explain why infections are becoming more common in older people. The global demand for primary care services is rising as a result of the increasing geriatric population. This boosts the need for diagnostics around the world, which is fueling market expansion.

“Increasing Adoption of Point-of-care Testing Techniques”

Many clinicians see point-of-care (POC) testing as essential for the early detection of life-threatening circumstances because the results can be made available in real time. The adoption of point-of-care diagnostics and monitoring equipment is expected to increase in homes, medical offices, and hospitals.

Top competitors in the market are constantly introducing new POCT technologies, which have increased public testing as well as the variety of clinical applications that are readily available. Additionally, POCT is routinely used in all hospitals and is evolving into the gold standard for patient care in a variety of healthcare settings.

Therefore, the market is projected to have profitable growth prospects over the coming years due to an increase in different initiatives to raise awareness among people about the diagnosis of helicobacter pylori and the growing use of POC testing techniques globally.

What Could Possibly Hinder Helicobacter Pylori Non-Invasive Testing Demand?

“Strict Regulatory Standards and Lack of Qualified Specialists”

It is anticipated that the market will be hampered by low diagnostic rates, the asymptomatic nature of the infection, and strict regulatory standards. A shortage of qualified specialists in many low- and middle-income economies with limited healthcare resources is hampering market growth.

Which Region Holds a Leading Position in the Global Helicobacter Pylori Non-Invasive Testing Market?

“Government Efforts to Reduce H. pylori Infection Rates Driving Market Value in North America”

North America accounts for 50% share of the global market owing to changing healthcare reforms and the implementation of guidelines by healthcare agencies regarding helicobacter pylori non-invasive testing. These policies have redirected healthcare organizations and professionals to concentrate more on urea breath tests.

Government efforts to reduce H. pylori infection rates and an increase in the local supply of modern helicobacter pylori non-invasive testing devices are driving market growth in the region.

Country-wise Insights

How is the United States Complementing North American Market Growth?

“High Awareness of Infectious Disease Detection & Treatment”

The market in the United States is anticipated to experience rapid growth due to the implementation of helicobacter pylori non-invasive testing techniques by healthcare facilities. Rising awareness of infectious disease detection and treatment and the introduction of new products are all contributing to market growth.

Why Does Germany Account for a Leading Position in Europe?

“Increasing Adoption of Stool Antigen Tests in Germany”

The presence of major companies and rapid innovations in helicobacter pylori non-invasive testing systems are driving market growth in Germany. Increasing adoption of stool antigen tests is boosting market value in the country.

Will Japan Emerge as a Lucrative Market for Helicobacter Pylori Non-Invasive Testing?

“Growing Prevalence of Gastrointestinal Disorders”

The rapidly expanding pharmaceutical industry, increasing prevalence of gastrointestinal disorders, and rising geriatric population are driving market growth in Japan. An increase in disposable income, a growing medical tourism industry, and improved infrastructure facilities for diagnostic purposes are the elements fueling market revenue in Japan.

Category-wise Insights

Why is Demand for Urea Breath Tests Increasing Rapidly?

“Urea Breath Tests Gaining Traction Due to Their Excellent Clinical Sensitivity and High Accuracy in Detecting H. pylori”

Based on non-invasive test types, the market is divided into serology tests, urea breath tests, and stool antigen tests. Urea breath tests account for 50% share of the global market.

Excellent clinical sensitivity and high accuracy in detecting helicobacter pylori are anticipated to boost the demand for urea breath tests. Urea breath tests are non-invasive, precise, and safe for both pregnant women and young patients. Urea breath tests are also useful for the evaluation of post-treatment status.

Non-invasive urea breath tests are used to determine whether the digestive system has the helicobacter pylori bacterium. The effectiveness of helicobacter pylori infection treatment can also be determined using this method. A helicobacter pylori bacterium can attack the duodenum and stomach.

Which End User is Predicted to Gain a Prominent Market Share?

“Hospitals Most Popular Due to Their Excellent Quality of Care at Reasonable Costs”

The market is divided into hospitals, diagnostic labs, and clinics based on end user. Hospitals are gaining traction due to the availability of skilled specialists, and the increasing occurrence of conditions such as duodenal ulcers, stomach cancer, gastritis, and gastric ulcers, as well as infections of the small intestine.

The demand for helicobacter pylori non-invasive testing in hospitals is anticipated to be driven by a rise in healthcare spending as well as an increase in patients visiting hospitals due to gastric cancer. Hospitals tend to attract more patients since they provide high-quality care and promptly address patients' requirements, resulting in successful treatments at reasonable costs. The premium services offered by hospitals as a result of effective illness management strategies are driving market expansion.

Competitive Landscape

The market is expected to develop due to an increase in product approvals. Leading companies are focusing on quality control, pricing trends, technological innovations, and supply chain management. They are enhancing product standards and introducing advanced helicobacter pylori non-invasive testing techniques following safety regulations to lower the environmental impact.

For instance :

• Meridian Bioscience, Inc. offers its tests and assay kits to hospitals, reference laboratories, and other diagnostic manufacturers in more than 60 countries. Its helicobacter pylori testing products include the Premium Platinum HpSA PLUS or Premium H. Pylori. It is an in vitro qualitative procedure to detect the presence of helicobacter pylori bacteria in human stool.
• Exalenz Biosciences manufactures the H. Pylori IgG ELISA Kit, BreathID HP, BreathID Smart, and Breath ID Lab devices. These devices conduct a quick and accurate Urea Breath Test for diagnosing helicobacter pylori infection and confirming post-treatment eradication. The test is conducted in real-time by continuously sampling breath, eliminating the need for sample collection, labeling, transport, and analysis.

Key Segments of Helicobacter Pylori Non-Invasive Testing Industry Research

• By Non-invasive Test Type :

  • Serology Tests
  • Stool Antigen Tests
  • Urea Breath Tests

• By Test Type :

  • Laboratory-based Tests
  • Point-of-Care Tests

• By End User :

  • Hospitals
  • Diagnostic Labs
  • Clinics

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa